Search research articles
Contact Us
Filters
Showing results (1-10 of 20) with videos related to
Page
of 2
Sort By:
Cancer Investigation
|
March 4, 2025
Artificial Intelligence in Cancer Clinical Research: V. What We Have Learned About Human Intelligence from Artificial Intelligence
Gary Lyman, Nicole Kuderer
American Clinical Laboratory
|
May 8, 2002
Hepatitis B virus vaccine: cost effects and insurance coverage
Rama Ganguly, Gary Lyman, Brandon Lenox
Current Medical Research and Opinion
|
February 6, 2009
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
Gary Lyman, Anjana Lalla, Richard Barron, et al.
Cancer Treatment Reviews
|
March 14, 2003
Evidence-based oncology in cancer treatment reviews
Benjamin Djulbegovic, Robert Coleman, Rolf Stahel, et al.
Chemotherapy
|
February 21, 2012
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer
Derek Weycker, John Edelsberg, Alex Kartashov, et al.
Current Medical Research and Opinion
|
August 19, 2007
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto, Zhimei Liu, Quan Doan, et al.
Nature Cancer
|
April 30, 2020
Crowdsourcing a crisis response for COVID-19 in oncology
Aakash Desai, Jeremy Warner, Nicole Kuderer, et al.
Nature Cancer
|
February 5, 2022
Crowdsourcing a crisis response for COVID-19 in oncology
Aakash Desai, Jeremy Warner, Nicole Kuderer, et al.
Human Pathology
|
January 12, 2008
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast
Krisztina Hanley, Jianmin Wang, Patricia Bourne, et al.
Journal of Managed Care & Specialty Pharmacy
|
January 27, 2023
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
Saad Aslam, Edward Li, Elizabeth Bell, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 20) with videos related to
Sort By:
Page
of 2
Cancer Investigation
|
March 4, 2025
Artificial Intelligence in Cancer Clinical Research: V. What We Have Learned About Human Intelligence from Artificial Intelligence
Gary Lyman, Nicole Kuderer
American Clinical Laboratory
|
May 8, 2002
Hepatitis B virus vaccine: cost effects and insurance coverage
Rama Ganguly, Gary Lyman, Brandon Lenox
Current Medical Research and Opinion
|
February 6, 2009
Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States
Gary Lyman, Anjana Lalla, Richard Barron, et al.
Cancer Treatment Reviews
|
March 14, 2003
Evidence-based oncology in cancer treatment reviews
Benjamin Djulbegovic, Robert Coleman, Rolf Stahel, et al.
Chemotherapy
|
February 21, 2012
Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer
Derek Weycker, John Edelsberg, Alex Kartashov, et al.
Current Medical Research and Opinion
|
August 19, 2007
Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials
Lionel Pinto, Zhimei Liu, Quan Doan, et al.
Nature Cancer
|
April 30, 2020
Crowdsourcing a crisis response for COVID-19 in oncology
Aakash Desai, Jeremy Warner, Nicole Kuderer, et al.
Nature Cancer
|
February 5, 2022
Crowdsourcing a crisis response for COVID-19 in oncology
Aakash Desai, Jeremy Warner, Nicole Kuderer, et al.
Human Pathology
|
January 12, 2008
Lack of expression of androgen receptor may play a critical role in transformation from in situ to invasive basal subtype of high-grade ductal carcinoma of the breast
Krisztina Hanley, Jianmin Wang, Patricia Bourne, et al.
Journal of Managed Care & Specialty Pharmacy
|
January 27, 2023
Risk of chemotherapy-induced febrile neutropenia in intermediate-risk regimens: Clinical and economic outcomes of granulocyte colony-stimulating factor prophylaxis
Saad Aslam, Edward Li, Elizabeth Bell, et al.
Page
of 2